LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 27

Search options

  1. Article ; Online: Angiotensin receptor blockers could be superior to angiotensin-converting enzyme inhibitors in COVID-19 management: the potential role of bradykinin.

    Kelleni, Mina T

    Irish journal of medical science

    2024  

    Language English
    Publishing date 2024-03-26
    Publishing country Ireland
    Document type Letter
    ZDB-ID 390895-1
    ISSN 1863-4362 ; 0021-1265
    ISSN (online) 1863-4362
    ISSN 0021-1265
    DOI 10.1007/s11845-024-03679-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Repurposing metformin to manage idiopathic or long COVID Tinnitus: self-report adopting a pathophysiological and pharmacological approach.

    Kelleni, Mina T

    Inflammopharmacology

    2024  Volume 32, Issue 2, Page(s) 945–948

    Abstract: Chronic tinnitus is a common neurological disorder that affects millions of patients globally with no available successful pharmacotherapy. It can be extremely bothersome to some patients to the extent that it occasionally qualifies as a disability that ... ...

    Abstract Chronic tinnitus is a common neurological disorder that affects millions of patients globally with no available successful pharmacotherapy. It can be extremely bothersome to some patients to the extent that it occasionally qualifies as a disability that can hinder them from leading a normal life. In this short communication, the author discusses how he suffered from idiopathic tinnitus and how he managed to adopt a combined pathophysiological and pharmacological approach to the reason for the first time in the medical literature that low-dose metformin might be safely and effectively repurposed to manage at least a subset of tinnitus patients while discussing the potential role of adenosine receptor agonists as potential future tinnitus therapeutics.
    MeSH term(s) Male ; Humans ; Self Report ; Post-Acute COVID-19 Syndrome ; Tinnitus/drug therapy ; COVID-19
    Language English
    Publishing date 2024-01-31
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 1080058-x
    ISSN 1568-5608 ; 0925-4692
    ISSN (online) 1568-5608
    ISSN 0925-4692
    DOI 10.1007/s10787-023-01421-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Evolution of SARS CoV-2 Omicron subvariants BF.7 and XBB.1.5: Time to follow Africa and abort all COVID restrictions.

    Kelleni, Mina T

    The Journal of infection

    2023  Volume 86, Issue 4, Page(s) 405

    MeSH term(s) Humans ; COVID-19 ; Africa/epidemiology
    Language English
    Publishing date 2023-01-23
    Publishing country England
    Document type Letter
    ZDB-ID 424417-5
    ISSN 1532-2742 ; 0163-4453
    ISSN (online) 1532-2742
    ISSN 0163-4453
    DOI 10.1016/j.jinf.2023.01.027
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: SARS CoV-2 genetic jump to a new SARS CoV-3 pandemic: Let's be prepared.

    Kelleni, Mina T

    The Journal of infection

    2023  Volume 87, Issue 2, Page(s) 144

    MeSH term(s) Humans ; SARS-CoV-2/genetics ; COVID-19 ; Severe Acute Respiratory Syndrome ; Pandemics/prevention & control
    Language English
    Publishing date 2023-03-21
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 424417-5
    ISSN 1532-2742 ; 0163-4453
    ISSN (online) 1532-2742
    ISSN 0163-4453
    DOI 10.1016/j.jinf.2023.03.018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Real-world practice of the Egyptian Kelleni's protocol amid changing tropism of SARS-CoV-2 omicron BA.5.2.1.7, XBB 1.5 and CH.1.1 subvariants: a multi-purpose protocol.

    Kelleni, Mina T

    Inflammopharmacology

    2023  Volume 31, Issue 3, Page(s) 1559–1560

    Abstract: The Egyptian immune-modulatory Kelleni's protocol, including nitazoxanide as an integral component, is being safely and effectively practiced to manage SARS-CoV-2, RSV, influenza infections in pediatric, adult and pregnant patients with negligible ... ...

    Abstract The Egyptian immune-modulatory Kelleni's protocol, including nitazoxanide as an integral component, is being safely and effectively practiced to manage SARS-CoV-2, RSV, influenza infections in pediatric, adult and pregnant patients with negligible requirements for the relatively expensive diagnostic molecular tests. Most recently, Kelleni's protocol is being likewise used to manage potential norovirus infection which is currently confused with SARS-CoV-2 Omicron new enterotropic subvariants and the antihistaminic loratadine has been co-administered in selected patients. Notably, Africa has the least mandates, restrictions and SARS-CoV-2 vaccination rates and yet the least COVID-19 mortality.
    MeSH term(s) Adult ; Female ; Pregnancy ; Humans ; Child ; Egypt ; SARS-CoV-2 ; COVID-19 Vaccines ; COVID-19 ; Tropism
    Chemical Substances COVID-19 Vaccines
    Language English
    Publishing date 2023-03-16
    Publishing country Switzerland
    Document type Letter
    ZDB-ID 1080058-x
    ISSN 1568-5608 ; 0925-4692
    ISSN (online) 1568-5608
    ISSN 0925-4692
    DOI 10.1007/s10787-023-01180-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: The African Kelleni's roadmap using nitazoxanide and broad-spectrum antimicrobials to abort returning to COVID-19 square one.

    Kelleni, Mina T

    Inflammopharmacology

    2023  Volume 31, Issue 6, Page(s) 3335–3338

    Abstract: For over 3.5 years, SARS CoV-2 is continuing to evolve threatening to return all and any improvement the world has made into square one. In this clinically oriented systematic review and perspective, the author explains how the best current medical ... ...

    Abstract For over 3.5 years, SARS CoV-2 is continuing to evolve threatening to return all and any improvement the world has made into square one. In this clinically oriented systematic review and perspective, the author explains how the best current medical evidence is strongly supporting the use of the low cost, widely available and very safe nitazoxanide in early management of COVID-19, debates the relevant theoretical studies that negated or doubted this benefit, and suggests an African roadmap to preempt the worst-case scenario if or when a new SARS CoV-2 (sub) variant or even a new respiratory virus causes a new global surge of morbidity and mortality. Kelleni's protocol, including nitazoxanide as an integral component, is continuing to perfectly save lives of patients infected with many viruses, including SARS CoV-2 and the author stresses that respiratory RNA viruses are best managed with early pharmacological treatment. Broad-spectrum antimicrobials as nitazoxanide and azithromycin together with other therapeutics as non-steroidal anti-inflammatory drugs and the antihistaminic loratadine should be considered first to personalize the clinical management of COVID-19 and selected other alarming viral infections.
    MeSH term(s) Humans ; Anti-Infective Agents ; COVID-19 ; Nitro Compounds ; SARS-CoV-2 ; Thiazoles/therapeutic use ; Systematic Reviews as Topic
    Chemical Substances Anti-Infective Agents ; nitazoxanide (SOA12P041N) ; Nitro Compounds ; Thiazoles
    Language English
    Publishing date 2023-06-16
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 1080058-x
    ISSN 1568-5608 ; 0925-4692
    ISSN (online) 1568-5608
    ISSN 0925-4692
    DOI 10.1007/s10787-023-01263-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Real-life practice of the Egyptian Kelleni's protocol in the current tripledemic: COVID-19, RSV and influenza.

    Kelleni, Mina T

    The Journal of infection

    2022  Volume 86, Issue 2, Page(s) 154–225

    MeSH term(s) Humans ; Influenza, Human/epidemiology ; Egypt/epidemiology ; COVID-19 ; Respiratory Syncytial Virus Infections ; Respiratory Syncytial Virus, Human ; Influenza B virus
    Language English
    Publishing date 2022-12-10
    Publishing country England
    Document type Letter
    ZDB-ID 424417-5
    ISSN 1532-2742 ; 0163-4453
    ISSN (online) 1532-2742
    ISSN 0163-4453
    DOI 10.1016/j.jinf.2022.12.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment.

    Kelleni, Mina T

    SN comprehensive clinical medicine

    2021  Volume 3, Issue 4, Page(s) 919–923

    Abstract: In this manuscript, we discuss the expectations versus the real-world results of four repurposed COVID-19 drugs: tocilizumab, remdesivir, favipiravir, and dexamethasone from a clinical and pharmacovigilant point of view. We suggest that though the ... ...

    Abstract In this manuscript, we discuss the expectations versus the real-world results of four repurposed COVID-19 drugs: tocilizumab, remdesivir, favipiravir, and dexamethasone from a clinical and pharmacovigilant point of view. We suggest that though the results of two-phase III double-blind clinical trials have been less than expected, tocilizumab has a real remaining potential to treat selected critical cases of COVID-19 beyond clinical trials until more data are revealed. On the contrary, remdesivir, though its FDA approval, and favipiravir are least likely to benefit COVID-19 patients. Moreover, we recommend that the RECOVERY dexamethasone should only be considered for critical hospitalized COVID-19 patients and we urge physicians in developing countries to avoid using it in mild-moderate COVID-19 cases. Finally, we recommend considering a personalized risk-benefit ratio before a decision is made using any of these drugs.
    Language English
    Publishing date 2021-02-19
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2947211-8
    ISSN 2523-8973 ; 2523-8973
    ISSN (online) 2523-8973
    ISSN 2523-8973
    DOI 10.1007/s42399-021-00824-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: BCG vaccination potential for COVID-19: an analytical approach.

    Kelleni, Mina T

    Human vaccines & immunotherapeutics

    2021  Volume 17, Issue 8, Page(s) 2448–2450

    Abstract: In order to assess the possible protective potential of BCG vaccination as regards to COVID-19, we have analyzed BCG vaccination status and SARS CoV-2 morbidity and mortality in China and we have also examined other studies performed in other countries ... ...

    Abstract In order to assess the possible protective potential of BCG vaccination as regards to COVID-19, we have analyzed BCG vaccination status and SARS CoV-2 morbidity and mortality in China and we have also examined other studies performed in other countries to assess the potential of booster doses of BCG vaccination for adults. We have concluded that BCG vaccination early in life is highly unlikely to be a tool that might prevent SARS CoV-2 infection in adults. Furthermore, we have suggested that BCG vaccination potential benefit to decrease COVID-19 morbidity and mortality in children is confounded by many factors, e.g. age limitations of exposure and other vaccines. However, BCG vaccination booster doses in adults might be of protective value until the results of well-designed clinical trials are published to confirm, or refute, this potential.
    MeSH term(s) Adult ; BCG Vaccine ; COVID-19 ; Child ; China ; Humans ; SARS-CoV-2 ; Vaccination
    Chemical Substances BCG Vaccine
    Language English
    Publishing date 2021-03-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2664176-8
    ISSN 2164-554X ; 2164-5515
    ISSN (online) 2164-554X
    ISSN 2164-5515
    DOI 10.1080/21645515.2021.1885281
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Resveratrol-zinc nanoparticles or pterostilbene-zinc: Potential COVID-19 mono and adjuvant therapy.

    Kelleni, Mina T

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

    2021  Volume 139, Page(s) 111626

    Abstract: In this manuscript we provide the scientific basis to adopt a novel combination of two widely available nutraceuticals; resveratrol and zinc in management of COVID-19 recommending their administration using a nano-carrier based drug-delivery system. ... ...

    Abstract In this manuscript we provide the scientific basis to adopt a novel combination of two widely available nutraceuticals; resveratrol and zinc in management of COVID-19 recommending their administration using a nano-carrier based drug-delivery system. Resveratrol, a well-known antioxidant and anti-inflammatory triphenolic stilbene, is abundant in red grapes, red wine, dark chocolate, and peanut butter. Alternatively, pterostilbene-zinc combination might be also considered without using a nano-carrier. We recommend conducting prompt clinical trials to assess the potential of the suggested combinations as a monotherapy for mild COVID-19 with a potential to prevent its progression to moderate-severe disease for which we recommend their trial as an adjuvant therapy. Furthermore, the suggested combinations might also possess a pharmacotherapeutic potential that exceeds COVID-19 to various inflammatory, immunologic, and oncologic diseases.
    MeSH term(s) Antiviral Agents/therapeutic use ; COVID-19/drug therapy ; Drug Delivery Systems ; Humans ; Nanoparticles ; Resveratrol/therapeutic use ; Stilbenes/therapeutic use ; Zinc/therapeutic use
    Chemical Substances Antiviral Agents ; Stilbenes ; pterostilbene (26R60S6A5I) ; Zinc (J41CSQ7QDS) ; Resveratrol (Q369O8926L)
    Language English
    Publishing date 2021-04-21
    Publishing country France
    Document type Journal Article
    ZDB-ID 392415-4
    ISSN 1950-6007 ; 0753-3322 ; 0300-0893
    ISSN (online) 1950-6007
    ISSN 0753-3322 ; 0300-0893
    DOI 10.1016/j.biopha.2021.111626
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top